15 47 ()() ... 5678910111213141516171819202122232425 ... ()()
141 150, 466.

: - (-)

  1. #141

    -? 1 3 2 2 . / .
    ,
    2 . 3 . 2 .
    ( , 30 + )
    , , .
       

  2. #142
      marus'ka
    (, )
    10.08.2009
    35
    5,402

    1 . 2 /, , ) . - , , - )) ..
       

  3. #143

    23.09.2010
    ,
    45
    26,935

    ?
       

  4. #144
      marus'ka
    (, )
    10.08.2009
    35
    5,402

    ?
    ? , ? . ( ), ..
       

  5. #145

    23.09.2010
    ,
    45
    26,935

    . , ( ) .
       

  6. #146
      marus'ka
    (, )
    10.08.2009
    35
    5,402

    , , ... ? , - ...
       

  7. #147

    23.09.2010
    ,
    45
    26,935

    , . . ( ).
    .
       

  8. #148

    23.09.2010
    ,
    45
    26,935

    2001. !

    187 . , 1998 . 1999 ., 2 : (93 ) 400 2 3 , (94 ) - 500 2 3 .

    , (25,7 vs 25,0 ). , (=0,199), (=0,411) (=0,222). .

    , - , .http://www.antibiotic.ru/index.php?article=622
       

  9. #149

    23.09.2010
    ,
    45
    26,935

    , :
    http://kronportal.ru/forum/showthrea...)--/page40
    Bacteria might be involved in the development and persistence of inflammation in patients with Crohn's disease, and antibiotics could be used in therapy.
    Dr Cosimo Prantera and colleagues from Italy performed a clinical phase 2 trial to determine whether a gastroresistant formulation of rifaximin induced remission in patients with moderately active Crohn's disease.
    The research team performed a multicenter, randomized, double-blind trial of the efficacy and safety of 400, 800, and 1200 mg rifaximin-extended intestinal release, given twice daily to 402 patients with moderately active CD for 12 weeks.
    Data from patients given rifaximin-extended intestinal release were compared with those from individuals given placebo, and collected during a 12-week follow-up period.
    The team's primary end point was remission at the end of the treatment period.


    Remission was achieved by 54% of the patients given the 400-mg dose

    At the end of the 12-week treatment period, 62% of patients who received the 800-mg dosage of rifaximin-extended intestinal release were in remission, compared with 43% of patients who received placebo.
    The team observed that a difference was maintained throughout the 12-week follow-up period.
    Remission was achieved by 54% and 47% of the patients given the 400-mg and 1200-mg dosages of rifaximin-extended intestinal release, respectively.
    These rates did not differ from those of placebo.
    The team found that patients given the 400-mg and 800-mg dosages of rifaximin-extended intestinal release had low rates of withdrawal from the study because of adverse events.
    The team noted that withdrawal rates were significantly higher among patients given the 1200-mg dosage.
    Dr Prantera's team concludes, "Administration of 800 mg rifaximin-extended intestinal release twice daily for 12 weeks induced remission with few adverse events in patients with moderately active Crohn's disease."



    http://www.gastrohep.com/news/news.asp?id=108664
    , .
    - Prantera 2 .
    , , 400, 800 1200 - , 402 CD 12 .
    , - , , 12- .
    .


    54% , 400

    12- , 62% , 800 - , 43% , .
    , 12- .
    54% 47% , 400 1200 - .
    .
    , , 400 800 - - .
    , , 1200 .
    Prantera , " 800 - 12 ".
       

  10. #150

    , . , , , . , . . (1 6001 800 ) (3 ) .


    http://www.viferon.su/medikamentozna...tej/#more-3792
    "Fuer einen treuen Freund gibt es keinen Preis, nichts wiegt seinen Wert auf"
       

Thread Information

Users Browsing this Thread

2 . (0 2 )

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •